» Articles » PMID: 22014944

Octa-functional PLGA Nanoparticles for Targeted and Efficient SiRNA Delivery to Tumors

Overview
Journal Biomaterials
Date 2011 Oct 22
PMID 22014944
Citations 65
Authors
Affiliations
Soon will be listed here.
Abstract

Therapies based on RNA interference, using agents such as siRNA, are limited by the absence of safe, efficient vehicles for targeted delivery in vivo. The barriers to siRNA delivery are well known and can be individually overcome by addition of functional modules, such as conjugation of moieties for cell penetration or targeting. But, so far, it has been impossible to engineer multiple modules into a single unit. Here, we describe the synthesis of degradable nanoparticles that carry eight synergistic functions: 1) polymer matrix for stabilization/controlled release; 2) siRNA for gene knockdown; 3) agent to enhance endosomal escape; 4) agent to enhance siRNA potency; 5) surface-bound PEG for enhancing circulatory time; and surface-bound peptides for 6) cell penetration; 7) endosomal escape; and 8) tumor targeting. Further, we demonstrate that this approach can provide prolonged knockdown of PLK1 and control of tumor growth in vivo. Importantly, all elements in these octa-functional nanoparticles are known to be safe for human use and each function can be individually controlled, giving this approach to synthetic RNA-loaded nanoparticles potential in a variety of clinical applications.

Citing Articles

Nanotechnology approaches to drug delivery for the treatment of ischemic stroke.

Peng B, Mohammed F, Tang X, Liu J, Sheth K, Zhou J Bioact Mater. 2024; 43:145-161.

PMID: 39386225 PMC: 11462157. DOI: 10.1016/j.bioactmat.2024.09.016.


The landscape of nanoparticle-based siRNA delivery and therapeutic development.

Moazzam M, Zhang M, Hussain A, Yu X, Huang J, Huang Y Mol Ther. 2024; 32(2):284-312.

PMID: 38204162 PMC: 10861989. DOI: 10.1016/j.ymthe.2024.01.005.


Engineering siRNA therapeutics: challenges and strategies.

Ali Zaidi S, Fatima F, Zaidi S, Zhou D, Deng W, Liu S J Nanobiotechnology. 2023; 21(1):381.

PMID: 37848888 PMC: 10583313. DOI: 10.1186/s12951-023-02147-z.


Megakaryocyte membrane-wrapped nanoparticles for targeted cargo delivery to hematopoietic stem and progenitor cells.

Das S, Harris J, Winter E, Kao C, Day E, Papoutsakis E Bioeng Transl Med. 2023; 8(3):e10456.

PMID: 37206243 PMC: 10189472. DOI: 10.1002/btm2.10456.


Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer.

Ren S, Zhang Z, Guo R, Wang D, Chen F, Chen X World J Gastroenterol. 2023; 29(13):1911-1941.

PMID: 37155531 PMC: 10122790. DOI: 10.3748/wjg.v29.i13.1911.


References
1.
Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Greenwald D . Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010; 328(5981):1031-5. PMC: 2881692. DOI: 10.1126/science.1183057. View

2.
Bastos R, Pante N, Burke B . Nuclear pore complex proteins. Int Rev Cytol. 1995; 162B:257-302. DOI: 10.1016/s0074-7696(08)62619-4. View

3.
Frankel A, Pabo C . Cellular uptake of the tat protein from human immunodeficiency virus. Cell. 1988; 55(6):1189-93. DOI: 10.1016/0092-8674(88)90263-2. View

4.
Judge A, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A . Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest. 2009; 119(3):661-73. PMC: 2648695. DOI: 10.1172/JCI37515. View

5.
Cheng C, Saltzman W . Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials. 2011; 32(26):6194-203. PMC: 3130098. DOI: 10.1016/j.biomaterials.2011.04.053. View